Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
← catalyst calendarNCT07750158 · readout in 1,324 d
Sponsored by Exelixis (industry) · EXEL — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
600estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-06 | estimated | When the study began enrolling |
| Primary completion | 2030-04-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-04-05 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colorectal Cancer
Interventions
- Drug: Zanzalintinib — also filed as XL092
- Biological: MK-34574 — also filed as KEYTRUDA QLEX™, KEYTRUDA SC
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFDisease-Free Survival (DFS) in Zanzalintinib + MK-3475A Versus Placebo as Assessed by the Investigator
measured Up to 24 months
DFS in Zanzalintinib Monotherapy Versus Placebo as Assessed by the Investigator
measured Up to 24 months
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed